EGFR and non-small cell lung carcinoma: Previous studies have suggested that BRCA1 overexpression regulates drug response in chemotherapy, is related to the efficacy of EGFR-TKIs, and is prevalent in patients with NSCLC with early disease onset (Reguart et al., 2008; Sun et al., 2018).